Most of these data were abstracted from the cardiology literature, which has shown that the adjunctive use of GP IIb/IIIa inhibitors in the setting of percutaneous coronary intervention significantly reduces the rates of 30-day mortality and myocardial Infarction, as well as reduces the need for repeat revascularization procedures (Labinaz et al., 2007; Winchester et al., 2011). The gene discussed is ITGA2B; the disease is myocardial infarction.